BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30401353)

  • 1. Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders.
    Jacobs AA; Cangiano M
    Prim Care; 2018 Dec; 45(4):731-742. PubMed ID: 30401353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
    Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
    J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
    Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
    Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
    Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
    Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.
    Korthuis PT; McCarty D; Weimer M; Bougatsos C; Blazina I; Zakher B; Grusing S; Devine B; Chou R
    Ann Intern Med; 2017 Feb; 166(4):268-278. PubMed ID: 27919103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
    Herscher M; Fine M; Navalurkar R; Hirt L; Wang L
    Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania.
    Kawasaki S; Francis E; Mills S; Buchberger G; Hogentogler R; Kraschnewski J
    J Subst Abuse Treat; 2019 Nov; 106():58-64. PubMed ID: 31540612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Shelby Clinic Medication-Assisted Treatment for Opioid Addiction.
    Penn CL
    J Ark Med Soc; 2016 Aug; 113(2):30-32. PubMed ID: 30047628
    [No Abstract]   [Full Text] [Related]  

  • 13. Re-purposing anticoagulation clinics: expanding access to opioid agonist therapy in primary care settings.
    Lagisetty P; Heisler M; Bohnert A
    Addiction; 2017 Mar; 112(3):384-385. PubMed ID: 27550143
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
    Breen CT; Fiellin DA
    J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
    Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 20. Medication-Assisted Treatment of Adolescents With Opioid Use Disorders.
    COMMITTEE ON SUBSTANCE USE AND PREVENTION
    Pediatrics; 2016 Sep; 138(3):. PubMed ID: 27550978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.